Introduction {#S0001}
============

Osteosarcoma (OS), which mainly involves long tubular bone, is a common primary bone tumor among children, adolescents, and young adults.[@CIT0001] Though there are many improvements in the treatment of OS patients, such as surgery, radiotherapy or chemotherapy, the 5-year survival rate of patients with advanced OS was only 30--40%, and OS patients still have the risk of relapse and cancer metastasis.[@CIT0002]--[@CIT0005] However, the mechanism of OS progression remains unclear.

Warburg effect is a phenomenon that cancer cells mainly relied on aerobic glycolysis to generate the energy needed for cellular processes, while the normal cells depended on mitochondrial oxidative phosphorylation. Synchronously, relevant research has showed that cancer cells change their metabolic way to meet the high growth rate for energy, which may provide new insight into the process of adaptation of cancer cells.[@CIT0006] Accelerated glucose transport, aerobic glycolysis and lactate production were the main characteristics of Warburg effect.[@CIT0007] Warburg effect was reported in many cancers, such as breast cancer,[@CIT0008] ovarian cancer,[@CIT0009] lung cancer,[@CIT0010] and OS.[@CIT0011]

Long non-coding RNAs (lncRNAs), a class of non-coding RNAs with \>200 nucleotides (nts) in length, have been reported to function as competing endogenous RNAs (ceRNAs) to regulate the expression of miRNAs, and further affect the deposition of target protein.[@CIT0012] Furthermore, dysregulation of lncRNAs has been reported in diverse cancers including OS. For instance, previous studies indicated that lncRNA MALAT1,[@CIT0013] SNHG1,[@CIT0014] and HOST2[@CIT0015] were significantly up-regulated in OS tissues and cells. Notably, lncRNA FEZF1-AS1 was also reported to regulate tumor progression in various cancers, such as ovarian cancer,[@CIT0016] pancreatic cancer,[@CIT0017] and OS.[@CIT0018] In addition, lncRNA FEZF1-AS1 was documented to participate in Warburg effect in colorectal cancer[@CIT0019] and pancreatic ductal adenocarcinoma.[@CIT0020] However, the biological mechanism of FEZF1-AS1 was rarely reported in OS.

MicroRNAs (miRNAs), a class of non-coding RNAs with about 18--23 nts in length, can suppress target gene expression by inhibiting message RNAs (mRNAs) translation or by mediating the degradation of mRNAs.[@CIT0021] Moreover, some studies confirmed that the aberrant expression of miRNAs was closely associated with OS progression. For example, miR-211-5p,[@CIT0022] miR-885-5p,[@CIT0023] and miR-142-5p[@CIT0024] were markedly decreased in OS tissues and cells and acted as tumor suppressors by repressing cell proliferation, migration, invasion, as well as promoting cell apoptosis in OS development. Intriguingly, prior reports showed that miR-144 could hinder OS growth and metastasis by the target genes, such as ROCK1[@CIT0025] TAGLN[@CIT0026] and EZH2,[@CIT0027] suggesting the vital role of miR-144 in OS development.

CXC motif chemokine receptor 4 (CXCR4), a 352-amino acid rhodopsin-like transmembrane G protein-coupled cell surface receptors, is a crucial mediator in tumor progression in many cancers.[@CIT0028] Also, accumulating evidence validated that CXCR4 overexpression promoted tumor progression in OS.[@CIT0029],[@CIT0030] However, the biological mechanism of miR-144 and CXCR4 in OS is still unknown.

In this study, we found that FEZF1-AS1 was increased in OS tissues and cells, and the knockdown of FEZF1-AS1 suppressed growth and Warburg effect. Moreover, bioinformatics analysis discovered that FEZF1-AS1 had some complementary pairing with miR-144, and CXCR4 was an underlying target gene of miR-144 in OS cells. Therefore, we aimed to explore whether FEZF1-AS1 could regulate OS progression partly through the miR-144/CXCR4 axis.

Materials and Methods {#S0002}
=====================

Tissue Sample {#S0002-S2001}
-------------

The study was permitted by the Ethics Committee of The Second Hospital of Jilin University, and performed according to the Declaration of Helsinki Principles. Forty-two OS tissues and these corresponding adjacent normal tissues were obtained from The Second Hospital of Jilin University. All tissues were frozen at −80°C for the following experiments. Written informed consent was provided by all OS patients or their guardians.

Cell Culture {#S0002-S2002}
------------

Two human osteosarcoma cell lines Saos-2 (HTB-85) and HOS (CRL-1543), as well as human osteoblast cell line hFOB 1.19 (CRL-11372) were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). All cells were cultivated in RPMI‑1640 medium (Thermo Fisher Scientific, Rockville, MD, USA) containing 10% fetal bovine serum (Thermo Fisher Scientific) and 1% penicillin/streptomycin (Invitrogen, Carlsbad, CA, USA) in an incubator with the parameters of 37°C and 5% CO~2~.

Cell Transfection {#S0002-S2003}
-----------------

Small interference RNA (siRNA) targeting FEZF1-AS1 (si-FEZF1-AS1) and its control si-NC, FEZF1-AS1 overexpression vector (FEZF1-AS1) and empty vector (pcDNA), miR-144 mimics (miR-144) and its control (miR-NC), miR-144 inhibitor (anti-144) and its control (anti-NC) were bought from GenePharma (Shanghai, China). Transfection was performed by using Lipofectamine 2000 Reagent (Invitrogen) according to the manual.

Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) {#S0002-S2004}
----------------------------------------------------------

Total RNA from Saos-2, HOS and hFOB 1.19 cells were extracted using miRNeasy Mini Kit (Qiagen, Valencia, CA, USA). Then, the concentration of RNA samples was detected using NanoDrop 2000c (Thermo Fisher Scientific), and cDNA was synthesized using miScript RT Kit (TaKaRa, Dalian, China). QPCR was conducted using SYBR Premix Ex Taq II (TaKaRa) on ABI Prism 7700 Sequence Detection System (Thermo Fisher Scientific). The relative expression of FEZF1-AS1, miR-144 and CXCR4 was calculated by the 2^−ΔΔCt^ method. The primers were synthesized in RiBoBio (Guangzhou, China), and list as follows: FEZF1-AS1: (Forward, 5ʹ-TTAGGAGGCTTGTTCTGTGT-3ʹ, Reverse, 5ʹ-GCGCAGGTACTTAAGAAAGA-3ʹ); miR-144: (Forward, 5ʹ -TACAGTATAGATGAT-3ʹ, Reverse, 5ʹ-GTGCAGGGTCCGAGGT-3ʹ); CXCR4: (Forward, 5ʹ-TCAGTGGCTGACCTCCTCTT-3ʹ, Reverse, 5ʹ-CTTGGCCTTTGACTGTTGGT-3ʹ); GAPDH: (Forward, 5ʹ-TGTTCGTCATGGGTGTGAAC-3ʹ, Reverse, 5ʹ-ATGGCATGGACTGTGGTCAT-3ʹ) and U6: (Forward, 5ʹ-CTCGCTTCGGCAGCACA-3ʹ, Reverse, 5ʹ-AACGCTTCACGAATTTGCGT-3ʹ).

3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium Bromide (MTT) assay {#S0002-S2005}
-----------------------------------------------------------------------------

For cell proliferation assay, MTT (Sigma, St. Louis, MO, USA) was used to detect the proliferative capacity. In brief, cells (2×10^4^ per well) were injected into 96-well plates and cultivated until the cell confluency rate reached 80%. After transfection for 48 h, the cells were incubated for 0 h, 24 h, 48 h, and 72 hrs. Then, 20 μL of 5 mg/mL MTT solution (Sigma) was added into each well and incubated for another 4 hrs. Subsequently, dimethyl sulfoxide (DMSO, Sigma) was added into each well to dissolve the formazan. The colorimetric analysis at 490 nm was detected using a spectrophotometer (Thermo Fisher Scientific).

Glucose Uptake and Lactate Production Assay {#S0002-S2006}
-------------------------------------------

The levels of glucose and lactate were measured using Glucose Uptake Colorimetric Assay Kit (Sigma) and Lactic Acid Assay Kit (Jiancheng, China) in accordance with the manual, respectively.

Western Blot Assay {#S0002-S2007}
------------------

Total protein from cells was extracted using a protein extraction kit (Beyotime, Shanghai, China), and the concentration of protein was measured using BCA Protein Assay Kit (Beyotime). The protein sample was first separated by SDS-PAGE and then transferred onto a PVDF membrane (Millipore, Billerica, MA, USA). After being blocked in non-fat milk for 2 hrs, then the membrane was incubated in primary antibody HK2 (ab104836), Bcl-2 (ab194583), Bax (ab32503), CXCR4 (ab74012) or β-actin (ab8226) at 4°C overnight, followed by incubation with secondary antibodies for another 2hrs. The chemiluminescence intensity analysis was detected using eyoECL Plus Kit (Beyotime). Above antibodies were purchased from Abcam (Cambridge, MA, USA).

Cell Apoptosis Assay {#S0002-S2008}
--------------------

Fluorescein isothiocyanate (FITC) Annexin V Apoptosis Detection Kit (BD Biosciences, USA) was used to assess the cell apoptosis rate. In brief, the cultivated cells were suspended in binding buffer and then incubated with Annexin V-FITC and propidium iodide (PI) for 10mins in the dark. Then, the treated cells were analyzed by flow cytometry (BD Biosciences).

Dual-Luciferase Reporter Assay {#S0002-S2009}
------------------------------

The putative binding sites between miR-144 and FEZF1-AS1 or CXCR4 were predicted by DIANA tools ([<http://diana.imis.athena-innovation.gr>]{.ul}). The sequences of FEZF1-AS1, CXCR4 3ʹUTR and their negative mutants were cloned and then inserted into psiCHECK2 vector (Promega, Madison, WI, USA) to synthesize luciferase reporter plasmids, namely FEZF1-AS1-WT, FEZF1-AS1-MUT, CXCR4-WT or CXCR4-MUT. In Saos-2 and HOS cells, miR-144 mimics (miR-NC) and the luciferase reporter were co-transfected using Lipofectamine 2000. Following incubation for 48 hrs, Dual-Luciferase^®^ Reporter Assay system (Promega) was used to detect the luciferase activity.

RNA Immunoprecipitation (RIP) Assay {#S0002-S2010}
-----------------------------------

For RIP assay, EZ-Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Millipore) was used to enrich the fragment of FEZF1-AS1 or CXCR4. The lyase sample of cells transfected with miR-144 or miR-NC was incubated with magnetic beads conjugated with anti-Ago2 or IgG antibody. Then, the enrichment of FEZF1-AS1 or CXCR4 was analyzed by qRT-PCR assay.

Statistical Analysis {#S0002-S2011}
--------------------

All data were presented as the means ± standard deviation (SD) from at least three independent experiments using GraphPad Prism 7 (GraphPad Inc., San Diego, CA, USA). The comparisons between the two groups were analyzed by Student's *t*-test and differences among three or more groups were analyzed by one-way analysis of variance (ANOVA). *P*\< 0.05 was considered as statistically significant.

Results {#S0003}
=======

FEZF1-AS1 Was Up-Regulated in OS Tissues and Cells and Correlated with the Pathological Characteristics of OS Patients {#S0003-S2001}
----------------------------------------------------------------------------------------------------------------------

To explore the role of FEZF1-AS1 on OS, the qRT-PCR assay was used to detect the relative expression of FEZF1-AS1 in OS tissues and cells. The results exhibited that FEZF1-AS1 was apparently up-regulated in OS tissues and cells (Saos-2 and HOS) compared with that in corresponding adjacent normal tissues or human osteoblasts cells (hFOB 1.19) ([Figure 1A](#F0001){ref-type="fig"} and [B](#F0001){ref-type="fig"}). Moreover, the OS patients were divided into low group (n=18) and high group (n=24) by the median expression of FEZF1-AS1. The patients with high level of FEZF1-AS1 had lower survival rates, while low level of FEZF1-AS1 was associated with higher survival rates ([Figure 1C](#F0001){ref-type="fig"}). In addition, the chi-squared test presented that highly expressed FEZF1-AS1 was closely associated with clinical stage (p=0.0069), tumor size (p=0.0369) but uncorrelated with ages, gender and anatomic location ([Table 1](#T0001){ref-type="table"}). These data implicated that the level of FEZF1-AS1 was involved in the progression of OS.Table 1Association of FEZF1-AS1 Expression with Clinicopathological Features of OsteosarcomaClinicopathologic FeaturesN (%)Relative FEZF1-AS1 LevelP valueHigh (%)Low (%)Total cases42 (100)24 (57.1)18 (42.9)Age (years)P=0.5913 ≥2019 (45.2)10 (52.6)9 (47.4) \<2023 (54.8)14 (60.9)9 (39.1)GenderP=0.8527 Male20 (47.6)12 (60.0)8 (4.0) Female22 (52.4)12 (54.5)9 (45.5)Clinical stageP=0.0069 Ⅰ+ⅡA18 (42.9)6 (33.3)12 (66.7) ⅡB-Ⅲ24 (57.1)18 (75.0)6 (25.0)Tumor size (cm)P=0.0369 ≥517 (40.5)13 (76.5)4 (23.5) \<525 (59.5)11 (44.0)14 (56.0)Anatomic locationP=0.7890 Tibia/femur22 (64.3)13 (59.1)9 (40.9) Elsewhere20 (47.6)11 (55.0)9 (45.0) Figure 1FEZF1-AS1 is up-regulated in OS tissues, cells and correlated with the pathological characteristics of OS patients.**Notes:** (**A** and **B**) The level of FEZF1-AS1 in OS tissues (**A**) and cells (**B**) were measured by qRT-PCR. (**C**) The correlation between overall survival rate and the expression of FEZF1-AS1. \*\*\**P*\<0.001.

FEZF1-AS1 Knockdown Inhibited Cell Proliferation, Warburg Effect and Promoted Cell Apoptosis in Saos-2 and HOS Cells {#S0003-S2002}
--------------------------------------------------------------------------------------------------------------------

To investigate the function of FEZF1-AS1 in OS, FEZF1-AS1 was knocked down in this study. The qRT-PCR results confirmed the knockdown efficiency, demonstrated by the down-regulation of FEZF1-AS1 in Saos-2 and HOS cells ([Figure 2A](#F0002){ref-type="fig"}). Moreover, MTT assay, glucose uptake and lactate production assay results showed that FEZF1-AS1 silencing suppressed cell viability and the levels of glucose, lactate in Saos-2 and HOS cells ([Figure 2B](#F0002){ref-type="fig"}--[D](#F0002){ref-type="fig"}). As HK2 was the Warburg-effect-related protein,[@CIT0031] the Western blot assay exhibited that the protein level of HK2 was decreased in Saos-2 and HOS cells transfected with si-FEZF1-AS1 ([Figure 2E](#F0002){ref-type="fig"}). In addition, the flow cytometry and Western blot assay showed that the apoptotic rate and the protein level of pro-apoptosis factor Bax were apparently up-regulated and the protein level of apoptosis-inhibited protein Bcl-2 was dramatically down-regulated in Saos-2 and HOS cells transfected with si-FEZF1-AS1 ([Figure 2F](#F0002){ref-type="fig"} and [G](#F0002){ref-type="fig"}). Taken together, the depletion of FEZF1-AS1 restrained cell proliferation, Warburg effect, and induced cell apoptosis in Saos-2 and HOS cells.Figure 2FEZF1-AS1 knockdown inhibits cell proliferation, Warburg effect and promotes cell apoptosis in Saos-2 and HOS cells.**Notes:** (**A-G**) Saos-2 and HOS cells were transfected with si-FEZF1-AS1 or si-NC. (**A**) The level of FEZF1-AS1 in transfected cells was measured by qRT-PCR. (**B**) The cell viability in transfected cells was evaluated via MTT assay. (**C-E**) The levels of glucose (**C**), lactate (**D**) and the protein level of HK2 (**E**) were assessed by glucose uptake and lactate production assay and Western blot, respectively. (**F** and **G**) The apoptotic rate (**F**) and the protein levels of Bcl-2 and Bax (**G**) were detected by flow cytometry and Western blot, respectively. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001.

miR-144 Was Negatively Interacted with FEZF1-AS1 {#S0003-S2003}
------------------------------------------------

To explore the biological mechanism of FEZF1-AS1 in OS, DIANA tools was used to search the putative target of FEZF1-AS1. The result showed that miR-144 had complementary sequences with FEZF1-AS1 ([Figure 3A](#F0003){ref-type="fig"}). Following luciferase reporter assay implicated that the transfection of miR-144 contributed to the significant decrease of luciferase activity of FEZF1-AS1-WT reporter in Saos-2 and HOS cells, while the luciferase activity had no apparent change in miR-NC group; however, the luciferase activity of FEZF1-AS1-MUT reporter had no significant fluctuation in any group ([Figure 3B](#F0003){ref-type="fig"} and [C](#F0003){ref-type="fig"}). Also, the RIP assay indicated that FEZF1-AS1 was strikingly enriched by Ago2 antibody in Saos-2 and HOS cells transfected with miR-144 mimics in comparison with IgG control group ([Figure 3D](#F0003){ref-type="fig"} and [E](#F0003){ref-type="fig"}). In addition, the level of miR-144 was remarkably decreased in Saos-2 and HOS cells transfected with pcDNA-FEZF1-AS1, while the level of miR-144 showed the opposite trend in cells transfected with si-FEZF1-AS1 ([Figure 3F](#F0003){ref-type="fig"} and [G](#F0003){ref-type="fig"}). These data revealed that miR-144 was negatively interacted with FEZF1-AS1.Figure 3MiR-144 is negatively interacted with FEZF1-AS1.**Notes:** (**A**) The complementary binding sites between miR-144 and FEZF1-AS1. (**B** and **C**) The interaction between miR-144 and FEZF1-AS1 was predicted by dual-luciferase reporter assay. (**D** and **E**) The enrichment of FEZF1-AS1 in Saos-2 (**D**) and HOS (**E**) cells transfected with miR-144 mimics or miR-NC was detected via RIP assay. (**F** and **G**) The level of miR-144 in Saos-2 (**F**) and HOS (**G**) cells transfected with pcDNA-FEZF1-AS1 or si-FEZF1-AS1 were detected by qRT-PCR. \*\**P*\<0.01, \*\*\**P*\<0.001.

miR-144 Was Distinctly Reduced in OS Tissues and Cells, and miR-144 Overexpression Suppresses Cell Proliferation, Warburg Effect and Promotes Cell Apoptosis in Saos-2 and HOS Cells {#S0003-S2004}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To investigate the functions of miR-144 in OS, miR-144 mimics were transfected into Saos-2 and HOS cells. First, the level of miR-144 was measured in OS. The qRT-PCR results showed that the level of miR-144 was markedly reduced in OS tissues and cells ([Figure 4A](#F0004){ref-type="fig"} and [B](#F0004){ref-type="fig"}). Moreover, qRT-PCR results exhibited the transfection efficiency, presented as the dramatical up-regulation of miR-144 in Saos-2 and HOS cells ([Figure 4C](#F0004){ref-type="fig"}). Furthermore, MTT assay exhibited that miR-144 overexpression suppressed cell viability of Saos-2 and HOS cells ([Figure 4D](#F0004){ref-type="fig"}). Also, the glucose uptake and lactate production assay results showed that miR-144 upregulation constrained cell viability and the levels of glucose, lactate in Saos-2 and HOS cells ([Figure 4E](#F0004){ref-type="fig"} and [F](#F0004){ref-type="fig"}). Meanwhile, the Western blot assay results indicated that the protein level of HK2 was decreased in Saos-2 and HOS cells transfected with miR-144 mimics ([Figure 4G](#F0004){ref-type="fig"}). In addition, the flow cytometry and Western blot assay implied that the transfection of miR-144 mimics resulted in the notable increase of apoptotic rate, the protein level of Bax and the decrease of the protein level of Bcl-2 in Saos-2 and HOS cells ([Figure 4H](#F0004){ref-type="fig"} and [I](#F0004){ref-type="fig"}). These results demonstrated that the level of miR-144 was conspicuously down-regulated in OS tissues, cells, and miR-144 overexpression restrained cell proliferation, Warburg effect and promoted cell apoptosis in Saos-2 and HOS cells.Figure 4MiR-144 was lower expressed in OS tissues, cells, and miR-144 overexpression suppresses cell proliferation, Warburg effect and promotes cell apoptosis in Saos-2 and HOS cells.**Notes:** (**A** and **B**) The level of miR-144 in OS tissues (**A**), cells (**B**) was measured by qRT-PCR. (**C-I**) Saos-2 and HOS cells were transfected with miR-144 or miR-NC. (**C**) The level of miR-144 in transfected cells was measured by qRT-PCR. (**D**) The cell viability in transfected cells was evaluated via MTT assay. (**E-G**) The levels of glucose (**E**), lactate (**F**) and the protein level of HK2 (**G**) were assessed by glucose uptake and lactate production assay and Western blot, respectively. (**H** and **I**) The apoptotic rate (**H**) and the protein levels of Bcl-2 and Bax (**I**) were detected by flow cytometry and Western blot, respectively. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001.

miR-144 Inhibitor Attenuated the Suppressive Effects on Cell Proliferation, Warburg Effect and the Promoted Effect on Cell Apoptosis in Saos-2 and HOS Cells Induced by FEZF1-AS1 Silencing {#S0003-S2005}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To investigate the biological mechanism and functions of FEZF1-AS1 and miR-144 in OS, si-FEZF1-AS1 and anti-144 were co-transfected into Saos-2 and HOS cells. The qRT-PCR results showed that the level of miR-144 was dramatically up-regulated in si-FEZF1-AS1-transfected Saos-2 and HOS cells, while anti-144 reversed the promotion effect ([Figure 5A](#F0005){ref-type="fig"}). Subsequently, the MTT assay indicated that miR-144 inhibitor mitigated the inhibitory effects on cell viability in Saos-2 and HOS cells transfected with si-FEZF1-AS1 ([Figure 5B](#F0005){ref-type="fig"}). Also, the glucose uptake and lactate production assay implicated that anti-144 receded the inhibitory effects on the levels of glucose and lactate in si-FEZF1-AS1-transfected Saos-2 and HOS cells ([Figure 5C](#F0005){ref-type="fig"} and [D](#F0005){ref-type="fig"}). Furthermore, Western blot assay exhibited that the protein level of HK2 was reverted in Saos-2 and HOS cells co-transfected with si-FEZF1-AS1 and anti-144 ([Figure 5E](#F0005){ref-type="fig"}). In addition, the Western blot and flow cytometry presented that anti-144 alleviated the promotion effects on cell apoptosis and the level of Bax, as well as the inhibitory effect on Bcl-2 expression level in Saos-2 and HOS cells caused by si-FEZF1-AS1 ([Figure 5F](#F0005){ref-type="fig"} and [G](#F0005){ref-type="fig"}). These results unraveled that miR-144 inhibitor blocked the suppressive effects on cell proliferation, Warburg effect and the promotion effect on cell apoptosis in Saos-2 and HOS cells induced by FEZF1-AS1 silencing.Figure 5MiR-144 downregulation attenuates the suppressive effects on cell proliferation, Warburg effect and the promotion effect on cell apoptosis in Saos-2 and HOS cells induced by FEZF1-AS1 silencing.**Notes:** (**A-G**) Saos-2 and HOS cells were transfected with si-FEZF1-AS1, si-FEZF1-AS1+anti-144 or their matched negative controls. (**A**) The levels of miR-144 (**A**) in transfected cells were detected by qRT-PCR. (**B**) The cell viability in transfected cells was evaluated via MTT assay. (**C-E**) The levels of glucose (**C**), lactate (**D**) and the protein level of HK2 (**E**) were assessed by glucose uptake and lactate production assay and Western blot, respectively. (**F** and **G**) The apoptotic rate (**F**) and the protein levels of Bcl-2 and Bax (**G**) were detected by flow cytometry and Western blot, respectively. \*\**P*\<0.01, \*\*\**P*\<0.001.

CXCR4 Was a Direct Target of miR-144 {#S0003-S2006}
------------------------------------

To illustrate the biological mechanism of miR-144 in OS, DIANA tools was used to predict the putative target of miR-144. The results exhibited that CXCR4 3ʹUTR had complementary binding site with miR-144 ([Figure 6A](#F0006){ref-type="fig"}). Dual-luciferase reporter assay indicated that the luciferase activity of CXCR4-WT reporter was strikingly decreased in Saos-2 and HOS cells transfected with miR-144 mimics compared to that in miR-NC group, while the luciferase activity of CXCR4-MUT reporter had no distinct change ([Figure 6B](#F0006){ref-type="fig"} and [C](#F0006){ref-type="fig"}). Following RIP assay also indicated that the transfection of CXCR4 drastically enriched miR-144 by Ago2 antibody than IgG antibody in Saos-2 and HOS cells ([Figure 6D](#F0006){ref-type="fig"} and [E](#F0006){ref-type="fig"}). In addition, Western blot assay results showed that the protein level of CXCR4 was apparently decreased in Saos-2 and HOS cells transfected with miR-144 mimics, while elevated in cells transfected with anti-miR-144 ([Figure 6F](#F0006){ref-type="fig"} and [G](#F0006){ref-type="fig"}). To sum, CXCR4 was negatively interacted with miR-144.Figure 6CXCR4 is a direct target of miR-144.**Notes:** (**A**) The complementary sequences between miR-144 and CXCR4 were predicted. (**B-E**) The interaction between miR-144 and CXCR4 was validated by dual-luciferase reporter assay (**B** and **C**) and RIP assay (**D** and **E**) in Saos-2 and HOS cells. (**F** and **G**) The level of CXCR4 in Saos-2 (**F**) and HOS (**G**) cells transfected with miR-144 mimics or anti-144 was detected by qRT-PCR. \*\**P*\<0.01, \*\*\**P*\<0.001.

FEZF1-AS1 Silencing Down-Regulated CXCR4 in Saos-2 and HOS Cells by Sponging miR-144 {#S0003-S2007}
------------------------------------------------------------------------------------

Firstly, the qRT-PCR results showed that the level of CXCR4 was notably upregulated in OS tissues and cells ([Figure 7A](#F0007){ref-type="fig"} and [B](#F0007){ref-type="fig"}). The scatter diagram presented that the level of CXVR4 was negatively linear correlated with miR-144, and positively linear correlated with FEZF1-AS1 ([Figure 7C](#F0007){ref-type="fig"} and [D](#F0007){ref-type="fig"}). To explore the interactions among FEZF1-AS1, miR-144 and CACR4 in OS, CXCR4 levels were explored in Saos-2, and HOS cells co-transfected FEZF1-AS1 and miR-144. Western blot assay implicated that the protein level of CXCR4 was obviously elevated in Saos-2 cells transfected with FEZF1-AS1, while the promoted impact was mitigated by miR-144 mimics in Saos-2 cells ([Figure 7E](#F0007){ref-type="fig"}). Also, the protein level of CXCR4 was conspicuously reduced in si-FEZF1-AS1 transfected HOS cells, while the transfection of anti-144 reversed the promotion effect ([Figure 7F](#F0007){ref-type="fig"}). Taken together, these data disclosed that FEZF1-AS1 modulated CXCR4 in Saos-2 and HOS cells by sponging miR-144.Figure 7FEZF1-AS1 silencing down-regulates CXCR4 in Saos-2 and HOS cells by sponging miR-144.**Notes:** (**A** and **B**) The level of CXCR4 in OS tissues (**A**) and cells (**B**) was measured by qRT-PCR. (**C** and **D**) The correlation between CXCR4 and miR-144 (**C**) or FEZF1-AS1 was analyzed (**D**). (**E** and **F**) The protein level of CXCR4 in Saos-2 cells transfected with FEZF1-AS1, FEZF1-AS1+miR-144 or their matched controls (**E**) or HOS cells transfected with si-FEZF1-AS1, si-FEZF1-AS1+anti-144 or their matched controls (**F**) were detected by Western blot. \*\**P*\<0.01, \*\*\**P*\<0.001.

Discussion {#S0004}
==========

Osteosarcoma (OS) is a common bone malignant tumor among children, adolescents, and young adults. Convincing evidence indicated that lncRNAs play crucial roles in the progression of various cancers. In this program, we focused on the mechanism and functions of lncRNA FEZF1-AS1 in OS. The results unraveled that lncRNA FEZF1-AS1 promoted OS progression partially through up-regulating CXCR4 expression by sponging miR-144.

Accumulating evidence documented that dysregulation of lncRNAFEZF1-AS1 associated with many processes in tumor progression, including OS. For instance, previous studies indicated that FEZF1-AS1 was notably up-regulated, and FEZF1-AS1 knockdown inhibited proliferation, invasion, epithelial-mesenchymal transition (EMT), and induced apoptosis in multiple cancers, such as colorectal cancer,[@CIT0019] ovarian cancer,[@CIT0016] pancreatic cancer,[@CIT0017] gastric cancer,[@CIT0032] and hepatocellular carcinoma.[@CIT0033] Also, lncRNA FEZF1-AS1 has been found to be associated with Warburg effect in many cancers including colorectal cancer,[@CIT0019] pancreatic ductal adenocarcinoma.[@CIT0020] In this study, we verified that lncRNA FEZF1-AS1 was highly expressed in OS tissues and cells (Saos-2 and HOS), compared with previous studies.[@CIT0018] Meanwhile, the chi-squared test indicated that highly expressed FEZF1-AS1 was closely correlated with the pathological characteristics of OS patients, such as clinical stage, tumor size. Furthermore, functional experiment implicated that FEZF1-AS1 silencing repressed cell proliferation, Warburg effect and induced cell apoptosis in Saos-2 and HOS cells. In addition, the patients with high level of FEZF1-AS1 had low overall survival rate compared to that in low level of FEZF1-AS1 group. To sum, lncRNA FEZF1-AS1 plays vital roles in OS progression.

It is well documented that the aberrant expression of miR-144 takes part in the tumor progression in various cancers, including OS. Yin et al demonstrated that miR-144 expression was apparently reduced in breast cancer, and miR-144 overexpression blocked cell proliferation, migration and invasion, as well as promoted cell cycle arrest and cell apoptosis.[@CIT0034] Another study reported that miR-144 could repress the malignancy of cervical cancer by inhibiting cell proliferation and invasion.[@CIT0035] In the present study, miR-144 was predicted as the putative target of FEZF1-AS1, and following dual-luciferase reporter assay and RIP assay validated this interaction. Subsequently, we validated that miR-144 was strikingly down-regulated in OS tissues and cells.[@CIT0026],[@CIT0027],[@CIT0036],[@CIT0037] Functionally, miR-144 overexpression restrained cell proliferation, Warburg effect and induced cell apoptosis in Saos-2 and HOS cells. Furthermore, FEZF1-AS1 depletion inhibited cell proliferation, Warburg effect and induced cell apoptosis by sponging miR-144. These data revealed that FEZF1-AS1 regulated OS progression by sponging miR-144.

Emerging evidence reported that CXCR4 played an important role in tumor progression, including OS. Actually, previous study showed that CXCR4 overexpression promoted tumor progression in OS.[@CIT0029],[@CIT0030] In this study, the interaction between miR-144 and CXCR4 was first predicted by DIANA tools and then verified by dual-luciferase reporter assay and RIP assay. CXCR4 was found to be apparently increased in OS tissues and cells. In addition, CXCR4 was negatively correlated with miR-144 and positively correlated with FEZF1-AS1. Furthermore, the restoration experiment implied that FEZF1-AS1 overexpression up-regulated the level of CXCR4 in Saos-2 cells by targeting miR-144. Rescue assay proved that FEZF1-AS1 silencing decreased the expression of CXCR4 via sponging miR-144 in HOS cells. To sum, lncRNA FEZF1-AS1 regulated OS progression via miR-144/CXCR4 axis.

In summary, lncRNA FEZF1-AS1, CXCR4 was dramatically up-regulated, and miR-144 was significantly down-regulated in OS tissues and cells. FEZF1-AS1 silencing or miR-144 overexpression impeded cell proliferation, Warburg effect and induced cell apoptosis in Saos-2 and HOS cells. Moreover, lncRNA FEZF1-AS1 served as a sponge of miR-144 to upregulate CXCR4 expression, thereby promoting OS progression, providing an underlying therapeutic target for OS treatment.
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